

D M Jiang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3329404/publications.pdf>

Version: 2024-02-01

45
papers

380
citations

949033

11
h-index

889612

19
g-index

45
all docs

45
docs citations

45
times ranked

774
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic characterization and identification of actionable variants in patients with locally advanced or metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2022, 40, 562-562.	0.8	0
2	The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210948.	1.4	2
3	Chemoradiotherapy Using Carboplatin plus Paclitaxel versus Cisplatin plus Fluorouracil for Esophageal or Gastroesophageal Junction Cancer. Oncology, 2021, 99, 49-56.	0.9	9
4	Significantly Minimizing Drug Wastage and the Cost of Cabazitaxel Used to Treat Metastatic Castration-Resistant Prostate Cancer. European Urology, 2021, 79, 177-179.	0.9	2
5	Recent Advances in the Management of Penile Cancer: A Contemporary Review of the Literature. Oncology and Therapy, 2021, 9, 21-39.	1.0	20
6	Defining cisplatin eligibility in patients with muscle-invasive bladder cancer. Nature Reviews Urology, 2021, 18, 104-114.	1.9	57
7	Lack of Evidence Does Not Equal Lack of Benefit: Neoadjuvant Chemotherapy and Trimodality Therapy in Selected Patients with Muscle-Invasive Bladder Cancer. Current Oncology Reports, 2021, 23, 36.	1.8	2
8	Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223. Cancer Medicine, 2021, 10, 5775-5782.	1.3	7
9	Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastric and esophageal cancers. Journal of Gastrointestinal Oncology, 2020, 11, 356-365.	0.6	7
10	Transitioning to a New Normal in the Post-COVID Era. Current Oncology Reports, 2020, 22, 73.	1.8	10
11	Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma. Cancer Medicine, 2020, 9, 3023-3032.	1.3	7
12	Current Management of Localized Muscle-Invasive Bladder Cancer: A Consensus Guideline from the Genitourinary Medical Oncologists of Canada. Bladder Cancer, 2020, 6, 363-392.	0.2	1
13	Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions. Current Oncology Reports, 2020, 22, 14.	1.8	16
14	Enfortumab Vedotin in urothelial cancer. Therapeutic Advances in Urology, 2020, 12, 175628722098019.	0.9	24
15	Application of the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to Assess the Value of Abiraterone and Enzalutamide in Advanced Prostate Cancer. JCO Oncology Practice, 2020, 16, e201-e210.	1.4	13
16	Patterns of disease, treatment, and outcomes of esophageal cancer arising within a previous radiation treatment field.. Journal of Clinical Oncology, 2020, 38, 328-328.	0.8	0
17	Clinicopathological features and treatment outcomes of young patients with gastric and esophageal cancers.. Journal of Clinical Oncology, 2020, 38, e16577-e16577.	0.8	0
18	Comprehensive genomic profiling (CGP) of metastatic castrate-sensitive prostate cancer (mCSPC) to reveal potential biomarkers and therapeutic targets.. Journal of Clinical Oncology, 2020, 38, 198-198.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Improving quality of health-related quality of life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate cancer (mPC).. Journal of Clinical Oncology, 2020, 38, 58-58.	0.8	0
20	Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations. Cancer Medicine, 2019, 8, 1584-1593.	1.3	18
21	Chemotherapy intensification for first-line treatment of poor-prognosis metastatic germ cell cancer is not yet ready for prime time. Canadian Urological Association Journal, 2019, 14, 48-49.	0.3	0
22	Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2019, 17, 38-45.	0.9	29
23	Prognostic significance of malnutrition in metastatic esophageal squamous cell carcinoma.. Journal of Clinical Oncology, 2019, 37, 171-171.	0.8	1
24	Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer. Oncotarget, 2019, 10, 2947-2958.	0.8	27
25	Are Surrogate Endpoints Unbiased Metrics in Clinical Benefit Scores of the ASCO Value Framework?. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1489-1496.	2.3	3
26	Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma (GEAC).. Journal of Clinical Oncology, 2019, 37, 162-162.	0.8	0
27	Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastroesophageal cancer.. Journal of Clinical Oncology, 2019, 37, 164-164.	0.8	0
28	Health-Related Quality of Life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate adenocarcinoma (mPCa) and urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2019, 37, 478-478.	0.8	2
29	Minimizing drug wastage (DW) and cost of cabazitaxel used to treat metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2019, 37, 6550-6550.	0.8	0
30	Building a CTU Orientation Handbook iPad application for first-year residents. Canadian Medical Education Journal, 2019, 10, e111-e121.	0.3	2
31	Prime time for immunotherapy in advanced urothelial cancer. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 24-32.	0.7	2
32	Application of the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to assess the value of abiraterone acetate (AA) and enzalutamide (E) in advanced prostate cancer: clinical value and cost considerations.. Journal of Clinical Oncology, 2018, 36, 276-276.	0.8	1
33	Outcomes for advanced HER2-positive gastroesophageal cancer by anatomical location: Experience from the Princess Margaret Cancer Centre.. Journal of Clinical Oncology, 2018, 36, 131-131.	0.8	0
34	Survival outcomes for de novo versus relapsed stage IV gastric and gastroesophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology, 2018, 36, 148-148.	0.8	0
35	Management of metastatic gastric and esophageal cancer in older adults.. Journal of Clinical Oncology, 2018, 36, 163-163.	0.8	0
36	Patterns of recurrence and outcomes after curative resection of locally advanced HER2-positive gastroesophageal cancer (HPGEC).. Journal of Clinical Oncology, 2018, 36, 147-147.	0.8	1

#	ARTICLE	IF	CITATIONS
37	Comparison of bimodality versus trimodality therapy for esophageal or gastroesophageal junction (GEJ) cancer: Experience from the Princess Margaret Cancer Centre.. Journal of Clinical Oncology, 2018, 36, 4066-4066.	0.8	0
38	Gastrointestinal (GI) cancer (CA) drugs approved by the US Food and Drug Administration (FDA): Clinical value and cost considerations.. Journal of Clinical Oncology, 2018, 36, 6619-6619.	0.8	0
39	Comparison of chemoradiotherapy (CRT) using carboplatin/paclitaxel (CP) versus cisplatin/5-FU (CF) for esophageal or gastroesophageal junctional (GEJ) cancer.. Journal of Clinical Oncology, 2017, 35, 4053-4053.	0.8	1
40	Do the American Society of Clinical Oncology (ASCO) Value Framework and the European Society of Medical Oncology (ESMO) Magnitude of Clinical Benefit Scale measure the same construct of clinical benefit?. Journal of Clinical Oncology, 2017, 35, 6509-6509.	0.8	3
41	Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2017, 35, 699-699.	0.8	0
42	Comparison of chemoradiotherapy (CRT) with carboplatin/paclitaxel (CP) versus cisplatin/5-FU (CF) for esophageal or junctional cancer: Experience from the Princess Margaret Cancer Centre.. Journal of Clinical Oncology, 2017, 35, 126-126.	0.8	0
43	Management of Epidermal Growth Factor Receptor Inhibitor-Induced Hypomagnesemia: A Systematic Review. Clinical Colorectal Cancer, 2016, 15, e117-e123.	1.0	19
44	Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer. Annals of Oncology, 2015, 26, 2102-2106.	0.6	37
45	Predictors of Pathologic Complete Response After Neoadjuvant Treatment for Rectal Cancer: A Multicenter Study. Clinical Colorectal Cancer, 2015, 14, 291-295.	1.0	57